Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 11/20 | 0.44 |
| ▸ | CTSD | P07339 | 4/20 | 0.44 |
| ▸ | GRPR | P30550 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31066631 | 0.93 | CALCRL (0.47) | CALCRLBACE1CTSDGRPROPRD1 | |
| SCHEMBL31475694 | 0.91 | CALCRL (0.46) | CALCRLBACE1CTSDGRPRKDM1A | |
| SCHEMBL29590889 | 0.83 | BACE1 (0.44) | CALCRLBACE1CTSDGRPRKDM1A | |
| SCHEMBL29575779 | 0.82 | CALCRL (0.49) | CALCRLBACE1CTSDGRPRKEAP1 | |
| SCHEMBL31475679 | 0.81 | BACE1 (0.55) | BACE1CTSDOPRD1 | |
| SCHEMBL31257003 | 0.80 | MEN1 (0.44) | CALCRLBACE1CTSDGRPRKDM1A | |
| SCHEMBL30930183 | 0.80 | MEN1 (0.42) | CALCRLBACE1CTSD | |
| SCHEMBL29630484 | 0.80 | KMT2A (0.43) | BACE1CTSD | |
| SCHEMBL30658575 | 0.79 | CALCRL (0.46) | CALCRLBACE1CTSD | |
| SCHEMBL29531595 | 0.79 | CALCRL (0.41) | CALCRLBACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129126-A1 | LONG-LASTING HEPATITIS VIRUS ENTRY INHIBITOR | Chengdu AODA Biotechnology Co., Ltd (CN) | 2025-04-24 | — | — | US | disclosed |
| CN-118574640-A | Medicine and method for treating limited chronic hepatitis B by nucleoside (nucleotide) medicines | 上海贺普药业股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-116510021-A | Medicine and method for treating limited chronic hepatitis B by nucleoside (nucleotide) medicines | 上海贺普药业股份有限公司 | 2023-08-01 | — | — | CN | disclosed |